KTTA — Pasithea Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.79m
- -$3.14m
Annual cashflow statement for Pasithea Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.041 | -2.17 | -11.7 | -15.5 | -13.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | — | -1.11 | -2.81 | -0.14 | 0.852 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.002 | 0.111 | 0.845 | 1.57 | -1.52 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.039 | -3.17 | -13.7 | -13.4 | -13.9 |
| Capital Expenditures | — | -0.021 | -0.107 | -0.034 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -2.82 | 0.433 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | -0.021 | -2.93 | 0.399 | 0 |
| Financing Cash Flow Items | — | 20.6 | 0 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.282 | 55.9 | -3.21 | -3.73 | 4.52 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.244 | 52.7 | -19.8 | -16.8 | -9.41 |